Pfizer Independent Medical Education
Request for Proposals (RFP)
HER2 Expression in Urothelial Carcinoma(UC)
Competitive Grant Program – Pfizer Internal Review ProcessOverview
This competitive grant program intends to create awareness ofongoing clinical trials for UC patients and the scientific data
supporting the potential impact of targeting HER2 in locallyadvanced/metastatic UC.

Geographic Scope/Location of Projects
Latin America (prioritizing: Argentina, Brazil, Chile, Mexico, Peru)
Asia Pacific (prioritizing: Australia, India, Japan, Singapore, SouthKorea, Taiwan, Thailand)

Project Types and Area of Interest
Potential applicants are encouraged to identify and address theeducational needs, barriers and gaps for physicians and all
healthcare professionals (HCPs) caring for patients with UC.
Under this RFP, grants will be offered to support programs that will
strengthen HCP understanding of clincal data in HER2 targeted
therapies in UC and awareness of ongoing clinical trials in this area.
The goal is to increase patient access to clinical trials and improve
equity and diversity in clinical trials.
Independent Medical Education proposals may include live and/orvirtual activities, enduring courses, resources and tools, technology
platforms and social media, or any combination of traditional orinnovative formats.

Key Milestones• Application submission deadline: October 7, 2024
• Anticipated decision notification date: November 4, 2024
• Anticipated project start date: December, 2024

Funding Range
Grant applications are expected to be in the approximate range of$10,000 to $100,000 USD depending on the size, scope, and reach of
the activities. Total budget available is $250,000 USD.

I. Eligibility
Geographic Scope/Location of Projects:•••Latin America (prioritizing: Argentina, Brazil, Chile, Mexico, Peru)
Asia Pacific (prioritizing: Australia, India, Japan, Singapore, South Korea, Taiwan, Thailand)
Proposals will be in-scope if they reach learners in 1 or more of these countries. Single country proposals
are in-scope. Regionally targeted proposals are also in-scope.

Applicant Eligibility Criteria
•

•
•

•
•
•

The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; hospitals,healthcare institutions (both large and small); professional organizations/medical societies; medicaleducation companies; patient advocacy organizations, and other entities with a mission related tohealthcare professional education and/or healthcare improvement.
Only organizations are eligible to receive grants, not individuals or physician-owned organizations(companies, non-profits, or medical practice groups.)
If the project involves multiple departments within an institution and/or between different institutions /organizations / associations, all institutions must have a relevant role and the requesting organizationmust have a key role in the project.
The applicant must be the project/program lead or an authorized designee of such individual (e.g.,project/program lead’s grant coordinator).
The project/program lead must be an employee or contractor of the requesting organization.
Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We
strongly recommend that applicants confirm this with their organization or institution prior to submitting anapplication. Grants awarded to organizations that are subsequently found to be unable to accept funding
directly from Pfizer Inc. may be subject to rescission.

II. Requirements
Date RFP Issued:•July 3, 2024

Clinical Area:•Oncology – Genitourinary – Urothelial Carcinoma

General Area of Interest for this RFP:
•Projects that will be considered for Pfizer support will focus on:• strengthening HCP understanding of investigational HER2 targeted therapies being studied in
UC in order to increase patient access to clinical trials and improve equity and diversity inclinical trials.
• increasing awareness of HER2-expression prevalence in UC and the importance of HER2
testing in metastatic UC.
• elevating understanding of the evolving unmet needs and clinical relevance of HER2expressing UC and potential impact of HER2-targeted therapy research.
Independent Medical Education proposals may include live and/or virtual activities, enduring
courses, resources and tools, technology platforms and social media, or any combination oftraditional or innovative formats.

2

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeuticor diagnostic agents will not be considered.

Target Audience:•

Medical oncologists, urologists, physicians, nurses, pharmacists, pathologists and other healthcareprofessionals involved in the care and treatment of patients with UC

Expected Approximate Monetary Range of Grant Applications:•••

Grant applications are expected to be in the approximate range of $10,000 to $100,000 USD dependingon the size, scope, and reach of the activities.
Individual projects requesting up to $100,000 USD will be considered. The estimated total available
budget related to this RFP is $250,000.
Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), andindirect costs.

Key Dates:••••

RFP release date: July 3, 2024
Grant Application due date: October 7, 2024
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
Anticipated Grant Award Notification Date: November 4, 2024
Grants will be distributed following a fully executed agreement.
Anticipated Approximate Project Start and End Dates: December 2024 to December 2025. Please notethat these dates are included as a guide only. Projects may be shorter or longer than this one-yearperiod.

How to Submit:•••••

Note: Please read this section carefully since applications submitted not following these instructions will
not be accepted and will be cancelled.
Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click “Createyour password”. [Note: there are individual portals for each grant application type. Please be sure to use
the URL above.]
Click the “Start A New Knowledge Gap Application" button.
In the application:• For the question “What type of request are you submitting?” select Response to a Request forProposal (RFP)• For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive
Grant Program?” select Yes• Select the following Competitive Grant Program Name: 2024 ONC LATAM & APAC HER2
Expression in UC IME• Select the following Primary Area of Interest: Oncology – Genitourinary - UC
Requirements for submission:
Complete all required sections of the online application and upload your project proposal (seeAppendix) in the General RFP Submission field.
If you encounter any technical difficulties with the website, please click the “Technical Questions” link atthe bottom of the page.
IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

3

Questions:•If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jacqueline
Waldrop (Jacqueline.Waldrop@pfizer.com), with the subject line “2024 ONC LATAM & APAC HER2
Expression in UC IME”

Grant Agreements:••••

If your grant is approved, your institution will be required to enter into a written grant agreement withPfizer. Please click here to view the core terms of the agreement.
Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless agenuine conflict exists as between applicable law and the terms of the relevant grant agreement.
Applicant is encouraged to share the core terms with counsel for approval prior to submitting anapplication.
Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment ofgrant funding may only be paid to the grantee organization.
This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.

Review and Approval Process:•Grant requests received in response to a general RFP are reviewed by Pfizer colleagues to make final
grant decisions.

Mechanism by which Applicants will be Notified:••

All applicants will be notified via email by the dates noted above.
Applicants may be asked for additional clarification during the review period.

References:•Albarrán V, Rosero DI, Chamorro J, Pozas J, Román MS, Barrill AM, et al., Her-2 Targeted Therapy
in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates. Int J Mol Sci.
2022 Oct 21;23(20):12659. doi: 10.3390/ijms232012659.
•Al Sukhun, Sana A., et al., Global Equity in Clinical Trials: An ASCO Policy Statement. JCO GlobalOncology Volume 10 March 14, 2024, https://doi.org/10.1200/GO.24.00015•Chan E, Boyiddle C, Scherrer E, Schwartz NRM, Yu J, Fang Q et al., Testing and Interpretation of
HER2 Protein Expression and Gene Amplification in Urothelial Carcinoma. USCAP 2024 Mar 23 - Mar 28,
2024 | Baltimore, Maryland.
•Hadadi A, Krause HB, Elliott A, Brown JT, Nazha B, Harik LR, et al.,The Genomic Landscape ofUrothelial Carcinoma with High and Low ERBB2/HER2 Expression. Journal of Clinical Oncology, Volume 41,
Number 6_suppl, https://doi.org/10.1200/JCO.2023.41.6_suppl.555.
•Lattanzi M, Niederhausern A, Zheng J, Bahadur N, Nichols C, Barton L, et al., Incidence and clinicaloutcomes of HER2-altered bladder cancer (BC) patients (pts). Journal of Clinical Oncology, Volume 40,
Number 6_suppl, https://doi.org/10.1200/JCO.2022.40.6_suppl.556.
•Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, et al., HER2-low expression inpatients with advanced or metastatic solid tumors. Ann Oncol. 2023 Nov;34(11):1035-1046. doi:
10.1016/j.annonc.2023.08.005. Epub 2023 Aug 22.
•Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-Drug Conjugates Targeting the Human Epidermal Growth
Factor Receptor Family in Cancers. Front Mol Biosci. 2022 Feb 28:9:847835. doi:
10.3389/fmolb.2022.847835. eCollection 2022.

4

About Pfizer Global Medical Grants
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g.,research, quality improvement, or education) to improve patient outcomes in areas of unmet medical needthat are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) thatprovides detail regarding a general area of interest, sets timelines for review and approval, and uses aninternal Pfizer review process to make final grant decisions. Organizations are invited to submit an application
addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible
for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer mustnot be involved in any aspect of project development, nor the conduct of the independent education program.

5

Appendix
General RFP Submission Requirements
Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals
should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit
exclusive of references. When uploading your Project Proposal please ensure it addresses the following
sections:Goals and Objectives••

Briefly state the overall goal of the project.
List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

Needs Assessment for the Project•

Include a description of your organization’s needs assessment for this proposed project which may
include a quantitative baseline data summary, initial metrics, or a project starting point (please cite dataon gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

Target Audience•Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit
from the project outcomes. Describe the overall population size as well as the size of your sample
population.

Project Design and Methods•

Describe the planned project, the educational approach, and the way the planned methods address theestablished need.

Innovation•

Explain what measures you have taken to assure that this project is original and does not duplicate otherprojects or materials already developed. Describe how this project builds upon existing work, pilot
projects, or ongoing projects developed either by your institution or other institutions.

Evaluation and Outcomes•In terms of the metrics used for the needs assessment, describe how your organization will determine if
the gap was addressed for the target group. Identify the sources of data your organization anticipatesusing to make the determination. Describe how your organization is expected to collect and analyze thedata. Explain the method used to control for other factors outside this project (e.g., use of a control groupor comparison with baseline data). Quantify the amount of change expected from this project in terms thetarget audience. Describe how your organization will determine if the target audience was fully engaged
in the project.

Dissemination Plan•

Describe how the project may have extended benefit beyond the grant. Will the teaching materials be
made available to others to use? Will there be tools or resources that are made publicly available
beyond the initial project. Describe how the project outcomes might be broadly disseminated.

Anticipated Project Timeline•Provide an anticipated timeline for your project including project start/end dates.

6Additional Information•

If there is any additional information you feel Pfizer should be aware of concerning the importance of thisproject, please summarize here.

Organization Detail•

Describe the attributes of the institutions / organizations / associations that will support and facilitate theexecution of the project and the leadership of the proposed project. Articulate the specific role of eachpartner in the proposed project.

Budget Detail•

Please include a budget narrative that describes in greater detail the line items specified in the budget
submitted within the application.

•While estimating your budget please keep the following items in mind:• Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeuticassets (prescription or non-prescription).
• Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.
Please click here for details. General organizational running costs such as legal fees, insurance,
heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs
are not specific to a grant request and therefore, should not appear as line items in budgets.
However, costs that are specific to the study (e.g., some countries require insurance to be taken out
on a per-study basis for clinical research) would be acceptable to be included as line items.

7